Kyntra Bio Inc
Veridion Score
Composite trend over time
Why is KYNB moving today?
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for KYNB.
KYNB insider activity
Kyntra Bio Inc
No multi-insider buying cluster in the last 90 days
Net buying: $36K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-09 | 2026-06-06 | DeLucia David | Insider | sell | $6.71 | 52 | 4,377 | $349 | SEC Form 4 |
| 2026-06-09 | 2026-06-06 | Wettig Thane | Insider | sell | $6.71 | 198 | 27,005 | $1K | SEC Form 4 |
| 2026-05-19 | 2026-05-14 | Wettig Thane | Insider | buy | $7.09 | 2,800 | 27,203 | $20K | SEC Form 4 |
| 2026-05-18 | 2026-05-14 | Wettig Thane | Insider | buy | $7.09 | 2,800 | 27,203 | $20K | SEC Form 4 |
| 2026-03-10 | 2026-03-06 | DeLucia David | Insider | sell | $6.84 | 60 | 4,429 | $410 | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 1 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moKYNB contract awards, year to date.
Public federal awards linked to this ticker.
KYNB lobbying filings, year to date.
Registered lobbying filings matched to Kyntra Bio Inc.